Carvedilol tablets
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-0594-2025
Blood pressure / heart
Carvedilol 25 mg tablet
Public data on carvedilol from CMS and FDA: what pharmacies have paid for it, how many generic applications FDA has approved, and whether it appears in FDA's shortage or recall records.
$0.0323
NADAC per ea (2026-11)
approximate acquisition cost, not a retail price
-7%
change over five years
peak $0.0422 in 2015-12
19
approved generic applications (ANDAs) on record for Carvedilol
12 with a product still marketed · first 2007
Not listed
in FDA's current shortage list
no matching FDA shortage entries
NADAC per unit, monthly
CARVEDILOL 25 MG TABLETShow as table
| Month | NADAC per unit ($) |
|---|---|
| 2013-11 | 0.03477 |
| 2014-02 | 0.03635 |
| 2014-05 | 0.03467 |
| 2014-08 | 0.03523 |
| 2014-11 | 0.03483 |
| 2015-02 | 0.03443 |
| 2015-05 | 0.03437 |
| 2015-08 | 0.03303 |
| 2015-11 | 0.03803 |
| 2016-02 | 0.03470 |
| 2016-05 | 0.03269 |
| 2016-08 | 0.03192 |
| 2016-11 | 0.03199 |
| 2017-02 | 0.03169 |
| 2017-05 | 0.03194 |
| 2017-08 | 0.03038 |
| 2017-11 | 0.03062 |
| 2018-02 | 0.02950 |
| 2018-05 | 0.02898 |
| 2018-08 | 0.03443 |
| 2018-11 | 0.03793 |
| 2019-02 | 0.03358 |
| 2019-05 | 0.03322 |
| 2019-08 | 0.03263 |
| 2019-11 | 0.03272 |
| 2020-02 | 0.03447 |
| 2020-05 | 0.03367 |
| 2020-08 | 0.03446 |
| 2020-11 | 0.03334 |
| 2021-02 | 0.03476 |
| 2021-05 | 0.03563 |
| 2021-08 | 0.03654 |
| 2021-11 | 0.03461 |
| 2022-02 | 0.03566 |
| 2022-05 | 0.03281 |
| 2022-08 | 0.03302 |
| 2022-11 | 0.03381 |
| 2023-02 | 0.03217 |
| 2023-05 | 0.03126 |
| 2023-08 | 0.03128 |
| 2023-11 | 0.03132 |
| 2024-02 | 0.03141 |
| 2024-05 | 0.02840 |
| 2024-08 | 0.02964 |
| 2024-11 | 0.02831 |
| 2025-02 | 0.02871 |
| 2025-05 | 0.03054 |
| 2025-08 | 0.03087 |
| 2025-11 | 0.03205 |
| 2026-02 | 0.03174 |
| 2026-05 | 0.03172 |
| 2026-08 | 0.03223 |
| 2026-11 | 0.03231 |
Source: CMS NADAC weekly files, generic rows, monthly median of weekly averages · data as of 2026-11. Figures can change and may contain errors in the source data. Check the original source before relying on them.
Recall records mentioning carvedilol
openFDA enforcement records, by year reported.
| 2025 | 14 |
| 2022 | 1 |
| 2021 | 4 |
| 2019 | 2 |
| 2015 | 2 |
| 2014 | 1 |
| 2013 | 1 |
25 records since 2012. A record is one product or lot, not one recall event. Combination products that contain carvedilol are included.
What these numbers mean
NADAC is what retail pharmacies pay on average to buy the drug, published by CMS. It does not include rebates and is not what you pay at the counter. ANDA counts include all strengths and forms and applications whose products are now discontinued.
Most recent recall records
Carvedilol tablets
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-0577-2025
Carvedilol tablets
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-0579-2025
Carvedilol tablets
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-0578-2025
Carvedilol tablets
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-0587-2025
Not health advice. GxRadar is for general information only. Nothing here is medical, pharmacy, legal or financial advice. Do not start, stop or change any medicine based on this site. Talk to your pharmacist or prescriber about your own situation.
Articles that mention carvedilol
6 GxRadar articles cite or discuss this drug.
Price histories · Data story · 5 min
What pharmacies pay for seven blood pressure generics, 2014 and 2026
At federal survey rates, 365 tablets each of seven common blood pressure generics cost pharmacies about $95 in October 2026, down from $1,403 in October 2014. One drug explains most of the drop.
Benchmarks & how prices are set · Explainer · 5 min
Why the same generic costs different amounts at different pharmacies
Cash quotes for the same three heart-failure generics ranged from $12 to almost $398 across 175 pharmacies in one 2016 study. Federal cost data show how little of that price is the drug itself.
Patents & exclusivity · Explainer · 7 min
Generic drug labeling, skinny labels and carve-outs
Why a generic's label must match the brand's, how section viii carve-outs create skinny labels, what the 2011, 2013 and 2026 Supreme Court decisions held, and which changes generics cannot make alone.
Benchmarks & how prices are set · Explainer · 6 min
The federal upper limit, Medicaid's ceiling on generic drug payments
The FUL caps Medicaid spending on generics at 175 percent of average manufacturer prices, or at pharmacy cost when that is higher. In October 2026 the pharmacy-cost floor set it for 59 percent of drug groups.
Recall data · Data story · 6 min
What FDA's Class II drug recall records show
Four in five drug recall records are Class II. GxRadar counted 14,602 of them by year, event and reason, and found manufacturing lapses on the rise and a second nitrosamine wave in 2025.
Distribution · Explainer · 6 min
Repackagers and relabelers, the firms that put generics in new bottles
How federal rules define repackagers and relabelers, why their NDCs and expiration dates differ from the original, and what FDA's NDC and recall data show about them.